With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

NYSE-listed shares of Novo Nordisk (NVO) traded over 1% lower on Friday afternoon after Bank of America lowered its price ...

BofA analyst Sachin Jain lowered the firm’s price target on Novo Nordisk (NVO) to DKK 910 from DKK 1,075 and keeps a Buy rating on the shares.

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

Morgan Stanley analyst Thibault Boutherin lowered the firm’s price target on Novo Nordisk (NVO) to DKK 600 from DKK 700 and keeps an Equal ...

Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results. Read why I rate NVO stock a strong buy right now.

Well before market open that morning, Morgan Stanley's Thibault Boutherin knocked his Novo Nordisk price target down to 600 Danish kroner ($86.67) per share; previously, this number was 700 kroner ...

As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued at more than $600 billion are becoming a distant memory.

Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy ...

Barclays has lowered its first-quarter 2025 estimates for Novo Nordisk (CSE:NOVOb) (NYSE:NVO) ahead of its Q1 2025 report, citing weaker-than-expected prescription volumes for key drugs Wegovy and ...

The high-profile Danish pharmaceutical company got a price-target cut from an analyst. That pundit remains lukewarm at best on the Wegovy maker's prospects. Well before market open that morning ...